Archive | Uncategorized RSS feed for this section

Hot Investor Mandate: Investment Firm Partnered with Family Office Invests in Early-Stage Therapeutics, Devices, Diagnostics Companies Across the USA

4 Feb

A firm dedicated to accelerating the growth of seed-stage life sciences companies operates in partnership with a USA-based family office. The firm invests $250-500K in early financing rounds within high-quality syndicates. The firm invests in companies based in the U.S.

The firm is seeking investments in next-generation therapeutics, medical device, and diagnostics companies. Within the therapeutics sector, the firm invests in cell, gene, oligonucleotide, and microbial therapies, as well as other targeted therapies for well-defined diseases. Typical investments occur at the stage of lead optimization and IND-enabling studies. Within MedTech, the firm invests in platforms leveraging novel biological insights, including cellular and molecular diagnostics, biomaterials, and bio-active implants. Typical investment stage is during late-stage product development approaching regulatory clearance and commercialization.

The firm does not have any specific company or management team requirements. The firm is a strategic as well as financial investor, helping companies develop relationships and accelerate growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Family Office Actively Seeking Medical Device & Diagnostics Investment Opportunities, as well as AI-Related Technologies

4 Feb

A family office based in the USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Make a Match that Matters

17 Dec

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireYou’ve likely heard it said that fundraising is a numbers game – this is true, but only half of the equation. It doesn’t matter how many investors you meet with if they are not a fit for your product and stage of development. In fact, the argument can be made that, although networking is inherently valuable, you waste time by not seeking out the right investors for you.

At Life Science Nation (LSN), the mission is to connect companies with capital, and that happens through many ways, but most importantly, through addressing the bottleneck of connecting fundraising founders with investors who are a fit. One of the most direct and powerful methods LSN delivers this is through the Innovator’s Pitch Challenge (IPC).

The IPC puts fundraising founders in front of relevant investors seeking assets in their stage and sector directly through a live pitch session with Q&A, as well as indirectly via a dedicated webpage hosting a long-format pitch video, as well as executive summary, pitch deck, and any supporting materials. Attendees have the opportunity to vote for best pitch, awarding the top three companies with free tickets to future RESI conferences to support their fundraising efforts.

December 18 is the deadline to apply for the Innovator’s Pitch Challenge at 3-Day Digital Redefining Early Stage Investments (RESI), taking place, January 11-13, 2021 as a part of LSN’s Healthtech Partnering Week, January 11-15, 2021. Applications are free, however, applicants are required to register for the conference, as well as pay an additional $500 pitching fee. Early bird pricing ends this week, so get your application in by December 18 and save!

Example of a Company’s Landing Page

See What Investors Are Saying about The Innovator’s Pitch Challenge

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”
William Kuziel, MedPro Investors
“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”
Mayank Taneja, OSF Healthcare
“I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”
Nat Brinn, VC23
“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”
Gary Gershony, Life Science Angels / BayMed Venture Partners

Successful Partnering: It Depends on You, but You’re Not in it Alone

17 Dec

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

Life Science Nation (LSN)’s Redefining Early Stage Investments (RESI) conference series enables fundraising executives to network and make connections with key industry players. Because of its unique focus and format, RESI presents valuable opportunities for early-stage companies to meet and partner with investors and strategic partners. However, even with the best systems, partnering can be challenging and competitive.

The conference format has changed radically this year. RESI has evolved from a 1-day, in-person conference to a 3-day digital conference with non-stop partnering serving a global community. Additionally, LSN has added new conferences taking place within Healthtech Partnering Week: 4D Meets AI and Longevity, Health & Innovation, providing five full days of partnering.

LSN partnering events are designed to match fundraising executives with investors who are a fit for their product and stage of development, however, while some companies are consistently successful at getting many good investor meetings at each and every RESI conference they attend, while others struggle to get any meetings at all.

So what is the key to success?

Clearly, your degree of success is directly proportionate to the effort you put into it. There are 4 key elements to successful partnering:

  1. Create a compelling and complete profile for your company and yourself on the Partnering Platform
  2. Spend time on developing an outbound meeting request message
  3. Request as many meetings as possible
  4. Follow up frequently

Yes, this is a big task and a lot of work over the weeks leading up to a conference, but the effort you put into partnering will determine the outcome. Let’s have a look at each key element of your partnering strategy.

PROFILE

  1. Start with brief overview, similar to your “elevator pitch”, that simply introduces your company and describes what you do and what makes you special.
  2. Complete all of the sections in the profile with concise information that investors can easily navigate. The sections to complete are:
    • Technology Overview
    • Alliances and Collaborations
    • Supporting Metrics or Evidence
    • Current Financing Needs
    • Current Investors
    • Current Timeline
    • IP Status
    • Management Team Highlights
    • Recent milestones
    • Personal profiles of attendees at RESI
    • Upload your logo, your website and any supporting materials for investors to review, like an investor deck and executive summary

OUTBOUND MEETING REQUEST MESSAGE

Make your message compelling, as this is what the investor is going to see before deciding whether to look at your profile in more depth. Include the key points, without making it so long that you lose the interest of the reader. The key elements should include the following:

  1. Introduce yourself, your title, and the name of your company. Although obvious, you might be surprised by how many people don’t do this.
  2. Introduce your company. Give a brief overview of your company so that an investor can determine from the first sentence whether you are a fit for their investment mandate. Here are five key data points that are likely to affect investor fit:
    • Where your company is based
    • What sector your company is in (biotech, medtech, diagnostics, digital health, etc.)
    • The indication you are treating or problem you are trying to solve
    • Your product’s stage of development
  1. Key value proposition/elevator pitch. Use the next part of the email to describe the key value proposition of your technology. This should include a high-level description of the core technology and its major differentiators from currently available products or solutions. This is the core of your messaging and should reveal enough information to grab the investor’s interest.
  2. Stage of your fundraising You should clearly state where you are in the fundraising process (beginning, middle or end) and what the use of those proceeds will be. This way an investor can gauge if your round is a fit for their capital allocation.
  3. Reaffirm. You should do your homework on every investor you reach out to and reference a relevant data point to reaffirm the reason you are reaching out.
  4. Request the meeting.

REQUEST MANY MEETINGS

Keep in mind that investors are juggling their own agendas and are in high demand. Use the RESI Partnering Platform to determine which investors are a fit for you, and request meetings with all of those that you target. Our data show that the fundraising companies that get the most meetings sent out upwards of 50 invitations.

FOLLOW UP FREQUENTLY

A common pitfall in partnering is to not follow up sufficiently until you achieve your goal: to get that investor meeting. It is usually not sufficient to send a meeting request out and just wait for the answers to come rolling in.

The best strategy is to begin your outreach as soon as the Partnering Platform opens. This will give you time to follow up sufficiently with investors you want to meet with. After sending out all of your initial meeting requests, wait for about a week. At that point, send a message through the Partnering Platform using the “SEND A MESSAGE” option to all those who have not answered you after a week,  and change your messaging a bit, perhaps focusing each of your follow-up messages on a different area of your company (technology, market and unmet need, management or advisory team, etc.). Be organized and persistent. Use the platform messaging option, email (if you have Premier Partnering), LinkedIn, telephone… whatever it takes to get a response back.

If you follow these steps, you will see the results and have a better partnering experience.

HAPPY PARTNERING!

Venture Capital Firms Invest in Therapeutic Technologies Targeting Age-related Diseases in Europe & USA

16 Dec

A venture capital firm and company builder with headquarters in Western Europe and an additional office in the USA is allocating their funds primarily into companies in Europe and North America. The firm works on equity investments and venture creation, and the initial investment size is in the range from $1-5M in the Seed Round and additional $10-15M for subsequent rounds.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm is primarily focused on therapeutics, but is also considering advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, the firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat, but are also open to joining strong syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

USA Seed Fund Focuses on Women-led, B2C Healthcare Companies, Most Interested in Wearables, Software & Products supporting Patients/Caregivers and Aging in Place

16 Dec

A seed fund based in the US has an initial fund of $20 million. The firm typically makes seed investments of $500,000, with a majority of their capital reserved for follow-on rounds. The firm focuses on investing in women-led startups in healthcare. The firm focuses on US startups but will also consider opportunities outside of the US with a US-based entity.

The firm invests in healthcare companies in which consumers are involved in the use of or purchase of the product or service. The firm does not invest in drugs, PMA devices or in purely B2B technologies. Areas of interest include wearable medical devices, software used by patients or their caregivers, products that support seniors in aging in place, and products for wellness and prevention of disease. The firm does not invest in products based on unproven science, and the company needs to be able to demonstrate that the product or technology improved clinical outcomes; however, the firm is open to investing in pre-revenue products.

The firm only invests in companies with at least one woman on the executive team. The firm will invest in companies that face operational risk, but not companies that face scientific risk. The firm would consider investing in digital health companies that have not yet conducted pilot studies with customers provided these companies have a strong IP position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Mandate: Singapore VC Firm Invests Globally in Novel Medical Device, Therapeutics, Diagnostics and Digital Health Companies

1 Oct

A venture capital firm was founded in 2005 with headquarters in Singapore and Shanghai, with additional offices in Hong Kong, New York, and San Diego. The firm closed fifth fund, Fund V, of over $220M and is actively seeking investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in China and Southeast Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: